Microenvironmental stiffness enhances glioma cell proliferation by stimulating epidermal growth factor receptor signaling

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Umesh, Vaibhavi ^a,b   Rape, Andrew D ^a   Ulrich, Theresa A ^a,c   Kumar, Sanjay ^a  

^a University of California at Berkeley   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; NITROGEN;

ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; EXTRACELLULAR MATRIX; FOCAL ADHESION; G1 PHASE CELL CYCLE CHECKPOINT; GLIOMA CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RIGIDITY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; BIOMECHANICS; GENE EXPRESSION REGULATION; GLIOBLASTOMA; MECHANICS; MECHANOTRANSDUCTION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; S PHASE CELL CYCLE CHECKPOINT;

BIOMECHANICAL PHENOMENA; CELL PROLIFERATION; FOCAL ADHESIONS; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MECHANICAL PROCESSES; MECHANOTRANSDUCTION, CELLULAR; NITROGEN; PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; S PHASE CELL CYCLE CHECKPOINTS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84904401494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101771     Document Type: Article

References (66)

1. Agnihotri S, Burrell KE, Wolf A, Jalali S, Hawkins C, et al. (2013) Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp (Warsz) 61: 25-41. doi:10.1007/s00005-012-0203-0.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. doi:10.1056/NEJMoa043330. (Pubitemid 40349501)
3. Berens ME, Giese A (1999) "...those left behind." Biology and Oncology of Invasive Glioma Cells. Neoplasia N Y N 1: 208-219.
4. Unsgaard G, Rygh OM, Selbekk T, Müller TB, Kolstad F, et al. (2006) Intraoperative 3D ultrasound in neurosurgery. Acta Neurochir (Wien) 148: 235-253; discussion 253. doi:10.1007/s00701-005-0688-y.
5. Lopez JI, Kang I, You W-K, McDonald DM, Weaver VM (2011) In situ force mapping of mammary gland transformation. Integr Biol Quant Biosci Nano Macro 3: 910-921. doi:10.1039/c1ib00043h.
6. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, et al. (2005) Tensional homeostasis and the malignant phenotype. Cancer Cell 8: 241-254. doi:10.1016/j.ccr.2005.08.010. (Pubitemid 41317594)
7. Elkin BS, Azeloglu EU, Costa KD, Morrison B 3rd (2007) Mechanical heterogeneity of the rat hippocampus measured by atomic force microscope indentation. J Neurotrauma 24: 812-822. doi:10.1089/neu.2006.0169. (Pubitemid 46799273)
8. Lefranc F, Brotchi J, Kiss R (2005) Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol Off J Am Soc Clin Oncol 23: 2411- 2422. doi:10.1200/JCO.2005.03.089.
9. Ulrich TA, de Juan Pardo EM, Kumar S (2009) The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res 69: 4167-4174. doi:10.1158/0008-5472.CAN-08-4859.
10. Ananthanarayanan B, Kim Y, Kumar S (2011) Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform. Biomaterials 32: 7913-7923. doi:10.1016/j.biomaterials. 2011.07.005.
11. Belot N, Rorive S, Doyen I, Lefranc F, Bruyneel E, et al. (2001) Molecular characterization of cell substratum attachments in human glial tumors relates to prognostic features. Glia 36: 375-390. (Pubitemid 34010065)
12. Friedlander DR, Zagzag D, Shiff B, Cohen H, Allen JC, et al. (1996) Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. Cancer Res 56: 1939-1947.
13. Paulus W, Baur I, Schuppan D, Roggendorf W (1993) Characterization of integrin receptors in normal and neoplastic human brain. Am J Pathol 143: 154-163. (Pubitemid 24058169)
14. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, et al. (2010) Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6: 421-432. doi:10.1016/j.stem.2010.02.018.
15. Gingras MC, Roussel E, Bruner JM, Branch CD, Moser RP (1995) Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 57: 143-153.
16. Lathia JD, Li M, Hall PE, Gallagher J, Hale JS, et al. (2012) Laminin alpha 2 enables glioblastoma stem cell growth. Ann Neurol 72: 766-778. doi:10.1002/ ana.23674.
17. Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, et al. (2013) Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Mol Cancer Ther 12: 162-172. doi:10.1158/1535-7163.MCT-12-0701.
18. Natarajan M, Hecker TP, Gladson CL (2003) FAK signaling in anaplastic astrocytoma and glioblastoma tumors. Cancer J Sudbury Mass 9: 126-133.
19. Hirata E, Yukinaga H, Kamioka Y, Arakawa Y, Miyamoto S, et al. (2012) In vivo fluorescence resonance energy transfer imaging reveals differential activation of Rho-family GTPases in glioblastoma cell invasion. J Cell Sci 125: 858-868. doi:10.1242/jcs.089995.
20. Ivkovic S, Beadle C, Noticewala S, Massey SC, Swanson KR, et al. (2012) Direct inhibition of myosin II effectively blocks glioma invasion in the presence of multiple motogens. Mol Biol Cell 23: 533-542. doi:10.1091/mbc.E11- 01-0039.
21. Beadle C, Assanah MC, Monzo P, Vallee R, Rosenfeld SS, et al. (2008) The Role of Myosin II in Glioma Invasion of the Brain. Mol Biol Cell 19: 3357- 3368. doi:10.1091/mbc.E08-03-0319.
22. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17: 98. doi:10.1016/j.ccr.2009.12.020.
23. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710. doi:10.1101/gad.1596707. (Pubitemid 350070717)
24. Taylor TE, Furnari FB, Cavenee WK (2012) Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance. Curr Cancer Drug Targets 12: 197-209.
25. Lui VWY, Grandis JR (2002) EGFR-mediated cell cycle regulation. Anticancer Res 22: 1-11. (Pubitemid 34475268)
26. Jones TS, Holland EC (2011) Molecular pathogenesis of malignant glial tumors. Toxicol Pathol 39: 158-166. doi:10.1177/0192623310387617.
27. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, et al. (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63: 6962-6970. (Pubitemid 37322983)
28. Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, et al. (2001) Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61: 5349-5354. (Pubitemid 32694908)
29. Fan Q-W, Knight ZA, Goldenberg DD, Yu W, Mostov KE, et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 341-349. doi:10.1016/j.ccr.2006.03.029. (Pubitemid 43668732)
30. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, et al. (2009) Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 8: 1725-1738. doi:10.1158/1535-7163.MCT-08-1200.
31. Joy AM, Beaudry CE, Tran NL, Ponce FA, Holz DR, et al. (2003) Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 116: 4409-4417. doi:10.1242/jcs.00712. (Pubitemid 37369596)
32. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, et al. (2009) Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin signaling. Cell 139: 891-906. doi:10.1016/j.cell.2009.10.027.
33. Klein EA, Yin L, Kothapalli D, Castagnino P, Byfield FJ, et al. (2009) Cell-cycle control by physiological matrix elasticity and in vivo tissue stiffening. Curr Biol CB 19: 1511-1518. doi:10.1016/j.cub.2009.07.069.
34. Torsvik A, Røsland GV, Svendsen A, Molven A, Immervoll H, et al. (2010) Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res 70: 6393-6396. doi:10.1158/0008-5472.CAN-10-1305.
35. Stepanenko AA, Kavsan VM (2014) Karyotypically distinct U251, U373, and SNB19 glioma cell lines are of the same origin but have different drug treatment sensitivities. Gene 540: 263-265. doi:10.1016/j.gene.2014.02.053.
36. Owa T, Yoshino H, Yoshimatsu K, Nagasu T (2001) Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 8: 1487-1503. (Pubitemid 32894011)
37. Collin de l'Hortet A, Gilgenkrantz H, Guidotti J-E (2012) EGFR: A Master Piece in G1/S Phase Transition of Liver Regeneration. Int J Hepatol 2012. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461622/. Accessed 3 February 2014.
38. Collins NL, Reginato MJ, Paulus JK, Sgroi DC, Labaer J, et al. (2005) G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol 25: 5282-5291. doi:10.1128/MCB.25.12.5282-5291.2005. (Pubitemid 40781124)
39. Sahin Ö, Fröhlich H, Löbke C, Korf U, Burmester S, et al. (2009) Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol 3: 1. doi:10.1186/1752-0509-3- 1.
40. Brennan DJ, O'Connor DP, Rexhepaj E, Ponten F, Gallagher WM (2010) Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer 10: 605-617. doi:10.1038/nrc2902.
41. Kaneski CR, Constantopoulos G, Brady RO (1991) Effect of dimethylsulfoxide on the proliferation and glycosaminoglycan synthesis of rat prostate adenocarcinoma cells (PAIII) in vitro: isolation and characterization of DMSO-resistant cells. The Prostate 18: 47-58.
42. Grunt TW, Somay C, Pavelka M, Ellinger A, Dittrich E, et al. (1991) The effects of dimethyl sulfoxide and retinoic acid on the cell growth and the phenotype of ovarian cancer cells. J Cell Sci 100 (Pt 3): 657-666.
43. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, et al. (1996) Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 16: 1722-1733. (Pubitemid 26095645)
44. Yaish P, Gazit A, Gilon C, Levitzki A (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242: 933-935. (Pubitemid 19015255)
45. Yang L, Dan HC, Sun M, Liu Q, Sun X, et al. (2004) Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt. Cancer Res 64: 4394- 4399. doi:10.1158/0008-5472.CAN-04-0343.
46. Stabley D, Retterer S, Marshall S, Salaita K (2013) Manipulating the lateral diffusion of surface-anchored EGF demonstrates that receptor clustering modulates phosphorylation levels. Integr Biol 5: 659-668. doi:10.1039/ C3IB20239A.
47. Pelham RJ,Wang Y (1997) Cell locomotion and focal adhesions are regulated by substrate flexibility. Proc Natl Acad Sci U S A 94: 13661-13665.
48. Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, et al. (1998) Reciprocal interactions between β1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: A different perspective in epithelial biology. Proc Natl Acad Sci 95: 14821-14826. (Pubitemid 29003714)
49. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, et al. (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2: 249-256. doi:10.1038/35010517.
50. Lu Z, Jiang G, Blume-Jensen P, Hunter T (2001) Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 21: 4016-4031. doi:10.1128/MCB.21.12.4016-4031.2001. (Pubitemid 32476463)
51. Cabodi S, Moro L, Bergatto E, Boeri Erba E, Di Stefano P, et al. (2004) Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem Soc Trans 32: 438-442. doi:10.1042/BST0320438. (Pubitemid 38813532)
52. Mih JD, Marinkovic A, Liu F, Sharif AS, Tschumperlin DJ (2012) Matrix stiffness reverses the effect of actomyosin tension on cell proliferation. J Cell Sci 125: 5974-5983. doi:10.1242/jcs.108886.
53. Hwang Y, Chumbalkar V, Latha K, Bogler O (2011) Forced Dimerization Increases the Activity of ΔEGFR/EGFRvIII and Enhances Its Oncogenicity. Mol Cancer Res MCR 9: 1199-1208. doi:10.1158/1541-7786.MCR-11-0229.
54. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6: 56-68. doi:10.1038/nrm1549. (Pubitemid 40064899)
55. Benlimame N, He Q, Jie S, Xiao D, Xu YJ, et al. (2005) FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol 171: 505-516. doi:10.1083/jcb.200504124. (Pubitemid 41586939)
56. Srikanth M, Das S, Berns EJ, Kim J, Stupp SI, et al. (2013) Nanofiber-mediated inhibition of focal adhesion kinase sensitizes glioma stemlike cells to epidermal growth factor receptor inhibition. Neuro-Oncol 15: 319-329. doi:10.1093/neuonc/nos316.
57. Engler AJ, Sen S, Sweeney HL, Discher DE (2006) Matrix elasticity directs stem cell lineage specification. Cell 126: 677-689. doi:10.1016/j.cell.2006.06. 044. (Pubitemid 44233625)
58. Shih Y-RV, Tseng K-F, Lai H-Y, Lin C-H, Lee OK (2011) Matrix stiffness regulation of integrin-mediated mechanotransduction during osteogenic differentiation of human mesenchymal stem cells. J Bone Miner Res Off J Am Soc Bone Miner Res 26: 730-738. doi:10.1002/jbmr.278.
59. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, et al. (2011) Role of YAP/ TAZ in mechanotransduction. Nature 474: 179-183. doi:10.1038/nature10137.
60. Kook S-H, Jang Y-S, Lee J-C (2011) Involvement of JNK-AP-1 and ERK-NFκB signaling in tension-stimulated expression of Type I collagen and MMP-1 in human periodontal ligament fibroblasts. J Appl Physiol 111: 1575-1583. doi:10.1152/japplphysiol.00348.2011.
61. Wang N, Tytell JD, Ingber DE (2009) Mechanotransduction at a distance: mechanically coupling the extracellular matrix with the nucleus. Nat Rev Mol Cell Biol 10: 75-82. doi:10.1038/nrm2594.
62. Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci Off J Neurosurg Soc Australas 16: 748-754. doi:10.1016/j.jocn.2008.12.005.
63. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, et al. (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncol 12: 95-103. doi:10.1093/neuonc/nop015.
64. Halatsch M-E, Gehrke EE, Vougioukas VI, Bötefür IC, A-Borhani F, et al. (2004) Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J Neurosurg 100: 523-533. doi:10.3171/jns.2004.100.3.0523. (Pubitemid 38269082)
65. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, et al. (2008) Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine- Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme. J Clin Oncol 26: 5610-5617. doi:10.1200/JCO.2008.16.7510.
66. Stupp R, Hegi ME, Gorlia T, Erridge S, Grujicic D, et al. (2013) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, openlabel, controlled, phase III CENTRIC study. J Clin Oncol 31. Available: http://meetinglibrary.asco. org/content/112780-132. Accessed 8 May 2014.